These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 21377875

  • 41. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
    Henry JR, Li Y, Warshawsky AM, Brozinick JT, Hawkins ED, Misener EA, Briere DA, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Ajamie RT, Wilken B, Devanarayan V.
    Bioorg Med Chem Lett; 2006 Dec 15; 16(24):6293-7. PubMed ID: 17005393
    [Abstract] [Full Text] [Related]

  • 42. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
    Laurent D, Gounarides JS, Gao J, Boettcher BR.
    Diabetes Obes Metab; 2009 Jun 15; 11(6):632-6. PubMed ID: 19175377
    [Abstract] [Full Text] [Related]

  • 43. Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists.
    Casimiro-Garcia A, Bigge CF, Davis JA, Padalino T, Pulaski J, Ohren JF, McConnell P, Kane CD, Royer LJ, Stevens KA, Auerbach B, Collard W, McGregor C, Song K.
    Bioorg Med Chem; 2009 Oct 15; 17(20):7113-25. PubMed ID: 19783444
    [Abstract] [Full Text] [Related]

  • 44. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
    Pinelli A, Godio C, Laghezza A, Mitro N, Fracchiolla G, Tortorella V, Lavecchia A, Novellino E, Fruchart JC, Staels B, Crestani M, Loiodice F.
    J Med Chem; 2005 Aug 25; 48(17):5509-19. PubMed ID: 16107150
    [Abstract] [Full Text] [Related]

  • 45. Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.
    Yu J, Tang L, Yang Y, Ji R.
    Eur J Med Chem; 2008 Nov 25; 43(11):2428-35. PubMed ID: 18329751
    [Abstract] [Full Text] [Related]

  • 46. Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity.
    Le Naour M, Leclerc V, Farce A, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Lonchampt M, Dacquet C, Ktorza A, Berthelot P, Lebegue N.
    ChemMedChem; 2012 Dec 25; 7(12):2179-93. PubMed ID: 23047286
    [Abstract] [Full Text] [Related]

  • 47. Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD.
    Bhurruth-Alcor Y, Røst T, Jorgensen MR, Kontogiorgis C, Skorve J, Cooper RG, Sheridan JM, Hamilton WD, Heal JR, Berge RK, Miller AD.
    Org Biomol Chem; 2011 Feb 21; 9(4):1169-88. PubMed ID: 21157612
    [Abstract] [Full Text] [Related]

  • 48. Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.
    Cantin LD, Liang S, Ogutu H, Iwuagwu CI, Boakye K, Bullock WH, Burns M, Clark R, Claus T, delaCruz FE, Daly M, Ehrgott FJ, Johnson JS, Keiper C, Livingston JN, Schoenleber RW, Shapiro J, Town C, Yang L, Tsutsumi M, Ma X.
    Bioorg Med Chem Lett; 2007 Feb 15; 17(4):1056-61. PubMed ID: 17157013
    [Abstract] [Full Text] [Related]

  • 49. Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
    Li Z, Liao C, Ko BC, Shan S, Tong EH, Yin Z, Pan D, Wong VK, Shi L, Ning ZQ, Hu W, Zhou J, Chung SS, Lu XP.
    Bioorg Med Chem Lett; 2004 Jul 05; 14(13):3507-11. PubMed ID: 15177462
    [Abstract] [Full Text] [Related]

  • 50. Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
    Makadia P, Shah SR, Pingali H, Zaware P, Patel D, Pola S, Thube B, Priyadarshini P, Suthar D, Shah M, Giri S, Trivedi C, Jain M, Patel P, Bahekar R.
    Bioorg Med Chem; 2011 Jan 15; 19(2):771-82. PubMed ID: 21215640
    [Abstract] [Full Text] [Related]

  • 51. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S, Okada K, Kiyota K, Isogai S, Iwago M, Shinozaki T, Kitamura Y, Kohno Y, Murakami K.
    J Med Chem; 2010 Jul 08; 53(13):5012-24. PubMed ID: 20527969
    [Abstract] [Full Text] [Related]

  • 52. Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
    Aoki T, Asaki T, Hamamoto T, Sugiyama Y, Ohmachi S, Kuwabara K, Murakami K, Todo M.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2128-32. PubMed ID: 18280733
    [Abstract] [Full Text] [Related]

  • 53. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.
    Arch Pharm Res; 2009 May 15; 32(5):721-7. PubMed ID: 19471887
    [Abstract] [Full Text] [Related]

  • 54. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK, Chae YN, Choi SH, Moon HS, Son MH, Bae MH, Choi HH, Hur Y, Kim E, Park YH, Park CS, Kim JG, Lim JI, Shin CY.
    Eur J Pharmacol; 2011 Jan 15; 650(2-3):673-81. PubMed ID: 20974124
    [Abstract] [Full Text] [Related]

  • 55. Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists.
    Grether U, Bénardeau A, Benz J, Binggeli A, Blum D, Hilpert H, Kuhn B, Märki HP, Meyer M, Mohr P, Püntener K, Raab S, Ruf A, Schlatter D.
    ChemMedChem; 2009 Jun 15; 4(6):951-6. PubMed ID: 19326383
    [Abstract] [Full Text] [Related]

  • 56. CoMFA analysis of dual/multiple PPAR activators.
    Shah P, Mittal A, Bharatam PV.
    Eur J Med Chem; 2008 Dec 15; 43(12):2784-91. PubMed ID: 18321611
    [Abstract] [Full Text] [Related]

  • 57. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
    Rau O, Syha Y, Zettl H, Kock M, Bock A, Schubert-Zsilavecz M.
    Arch Pharm (Weinheim); 2008 Mar 15; 341(3):191-5. PubMed ID: 18275039
    [Abstract] [Full Text] [Related]

  • 58. PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents.
    Lanne B, Dahllöf B, Lindahl C, Ebefors K, Kanmert I, von Bahr H, Miliotis T, Nyström AC, Arnerup G, Paulsons I, Kerb S, Oakes N.
    J Proteome Res; 2006 Aug 15; 5(8):1850-9. PubMed ID: 16889406
    [Abstract] [Full Text] [Related]

  • 59. Synthesis and Structure-Activity Relationships of 2-Aminoacetamide Derivatives as Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists.
    Shibata Y, Kagechika K, Ota M, Yamaguchi M, Setoguchi M, Kubo H, Chiba K, Takano H, Akiyama C, Ono M, Nishi M, Usui H.
    Chem Pharm Bull (Tokyo); 2015 Aug 15; 63(8):591-602. PubMed ID: 26235167
    [Abstract] [Full Text] [Related]

  • 60. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C, Fruchart JC, Staels B.
    Curr Opin Pharmacol; 2006 Dec 15; 6(6):606-14. PubMed ID: 16973418
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.